Prilocaine

Prilocaine

SCHEMBL1813632

CCCNC(C)C(=O)Nc1ccccc1C.CCCNC(C)C(=O)Nc1ccccc1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Prilocaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A known ✓ P35498 2/20 1.00
SCN2A known ✓ Q99250 2/20 1.00
SCN3A known ✓ Q9NY46 2/20 1.00
PGR P06401 1/20 1.00
HPGD P15428 3/20 0.97
LMNA P02545 1/20 0.97
GAA P10253 1/20 0.97
MAPT P10636 1/20 0.97
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
HTR1A P08908 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ITGB3 P05106 2/20 0.49
ITGAV P06756 2/20 0.49
ALDH1A1 P00352 1/20 0.49
ANPEP P15144 1/20 0.48
ITGB1 P05556 1/20 0.48
ITGA5 P08648 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Prilocaine SCHEMBL866149 1.00 SCN1A (1.00) SCN1ASCN2ASCN3APGRHPGD
Prilocaine SCHEMBL30487874 1.00 SCN1A (1.00) SCN1ASCN2ASCN3APGRHPGD
Prilocaine SCHEMBL25468 1.00 SCN1A (1.00) SCN1ASCN2ASCN3APGRHPGD
Prilocaine SCHEMBL31333079 1.00 SCN1A (1.00) SCN1ASCN2ASCN3APGRHPGD
Prilocaine SCHEMBL25467 1.00 SCN1A (1.00) SCN1ASCN2ASCN3APGRHPGD
Prilocaine SCHEMBL9453293 0.98 HPGD (1.00) SCN1ASCN2ASCN3APGRHPGD
Prilocaine SCHEMBL330180 0.98 HPGD (1.00) SCN1ASCN2ASCN3APGRHPGD
Prilocaine SCHEMBL3829171 0.97 SCN1A (0.94) SCN1ASCN2ASCN3APGRHPGD
Prilocaine SCHEMBL18740859 0.92 SCN1A (0.85) SCN1ASCN2ASCN3APGRHPGD
Benzoyl Peroxide SCHEMBL3137165 0.88 SCN1A (0.77) SCN1ASCN2ASCN3APGRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3137065-A2 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES Pharnext (FR) 2017-03-08 EP disclosed
EP-3038614-A1 COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS Pharnext (FR) 2016-07-06 EP disclosed
WO-2015165948-A2 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES PHARNEXT (FR) 2015-11-05 WO disclosed
EP-2892519-A1 NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE Pharnext (FR) 2015-07-15 EP disclosed
WO-2015028659-A1 COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS PHARNEXT (FR) 2015-03-05 WO disclosed
WO-2014037412-A1 NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE PHARNEXT (FR) 2014-03-13 WO disclosed
EP-2560631-A2 BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS Pharnext (FR) 2013-02-27 EP disclosed
EP-2496226-A1 NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE Pharnext (FR) 2012-09-12 EP disclosed
WO-2012117076-A2 BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS PHARNEXT (FR) 2012-09-07 WO disclosed
WO-2011054759-A1 NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE PHARNEXT (FR) 2011-05-12 WO disclosed